CSL/UniQure’s Hemgenix To Enter Uncertain EU Market After Regulatory Nod

 
• By Ayisha Sharma

The firms’ one-time hemophilia B gene therapy has been approved in the EU just months after a US nod, but concerns remain about its prospects on a market that has seen several setbacks for other gene therapies.  

Removing part of a DNA helix, gene therapy concept
Hemgenix Delivers The Padua Gene Variant Of Factor IX To Patients • Source: Shutterstock

More from New Products

More from Scrip